Clinigen Group plc Grant of Share Options and PDMR notification (9352F)

TIDMCLIN

RNS Number : 9352F

Clinigen Group plc

01 March 2018

1 March 2018

Grant of Share Options and PDMR notification

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), announces that, on 1 March 2018, Debra Ainge (Chief Operating Officer of the Company and a PDMR) was granted share options over a total of 17,888 ordinary shares of 0.1 pence each ("Ordinary Shares") under the Clinigen Group Long Term Incentive Plan 2015. These options are nil cost options intended to vest on 16 October 2020 subject to the achievement of certain performance criteria.

The additional share options granted to Debra Ainge relate to the completion of the acquisition of Quantum Pharma plc and her assuming additional responsibility for the early access and 'on demand' access businesses within Unlicensed Medicines.

 
 Director/PDMR       Number   Total number   Total number      Total number 
                   of share       of share    of ordinary       of ordinary 
                    options        options         shares            shares 
                    granted       now held       now held        (excluding 
                                                             share options) 
                                                                as % issued 
                                                              share capital 
---------------  ----------  -------------  -------------  ---------------- 
 Debra Ainge         17,888         66,406         10,254             0.01% 
---------------  ----------  -------------  -------------  ---------------- 
 

The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.

Notification and public disclosure of transactions by person discharging managerial responsibilities.

 
 1     Details of the person discharging 
        managerial responsibilities/person 
        closely associated 
----  ------------------------------------------------------ 
 a)    Name                  Debra Ainge 
----  --------------------  -------------------------------- 
 2     Reason for the notification 
----  ------------------------------------------------------ 
 a)    Position/status       Chief Operating Officer 
                              - PDMR 
----  --------------------  -------------------------------- 
 b)    Initial               Initial Notification 
        notification 
        /Amendment 
----  --------------------  -------------------------------- 
 3     Details of the issuer, emission allowance 
        market participant, auction platform, 
        auctioneer or auction monitor 
----  ------------------------------------------------------ 
 a)    Name                  Clinigen Group plc 
----  --------------------  -------------------------------- 
 b)    Legal Entity          N/A 
        Identifier 
----  --------------------  -------------------------------- 
 4     Details of the transaction(s): section 
        to be repeated for (i) each type 
        of instrument; (ii) each type of 
        transaction; (iii) each date; and 
        (iv) each place where transactions 
        have been conducted 
----  ------------------------------------------------------ 
 a)    Description           Ordinary shares of 0.1 pence 
        of the financial      each 
        instrument,           GB00B89J2419 
        type of 
        instrument 
        Identification 
        code 
----  --------------------  -------------------------------- 
 b)    Nature of             Grant of Options 
        the transaction 
----  --------------------  -------------------------------- 
 c)    Currency              GBP 
----  --------------------  -------------------------------- 
 d)    Price(s)                Exercise      No. of shares 
        and volume(s)            Price 
----  --------------------  -------------  ----------------- 
                    Nil                          17,888 
  ---------------------------------------  ----------------- 
 
 e)    Aggregated             17,888 
        information            Nil 
        - Aggregated 
        volume 
        - Price 
        - Aggregated 
        total 
----  --------------------  -------------------------------- 
 f)    Date of               1 March 2018 
        the transaction 
----  --------------------  -------------------------------- 
 g)    Place of              London Stock Exchange, AIM 
        the transaction 
----  --------------------  -------------------------------- 
 

-Ends-

Contact details

 
 Clinigen Group plc                  Tel: [phone] 
                                      495010 
 Shaun Chilton, Group Chief 
  Executive Officer 
 Martin Abell, Group Chief 
  Financial Officer 
 
 Numis Securities Limited            Tel: +44 (0) 20 
                                      7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 RBC Capital Markets - Joint         Tel: +44 (0) 20 
  Broker                              7653 4000 
  Marcus Jackson / Elliot Thomas 
   / Jack Wood 
 
 Instinctif Partners                 Tel: +44 (0) 20 
                                      7457 2020 
 Melanie Toyne-Sewell / Alex 
  Shaw / Deborah Bell                Email: [e-mail] 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing ethical access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen acquired Quantum Pharma in November 2017.

For more information, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHFKADKBBKDOBB

(END) Dow Jones Newswires

March 01, 2018 04:00 ET (09:00 GMT)